Full Press Release Details
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that its Signatera molecular residual disease (MRD) test has received Medicare coverage through the Centers for Medicare & Medicaid Services’ (CMS) Molecular Diagnostics Services Program (MolDX) in hepatocellular carcinoma (HCC). The coverage includes serial Signatera testing in the surveillance setting for patients with early-stage HCC who have no post-surgi